

UnitedHealthcare Oxford Policy Update Bulletin: March 2022

Access a policy listed below for complete details on the latest updates. A comprehensive summary of changes is provided at the bottom of every policy document for your reference. To view a detailed version of this bulletin, click [here](#).

Clinical Policy Updates

Oxford Medical Benefit Drug Policies Relocated

Beginning May 1, 2022, Oxford will utilize the [UnitedHealthcare Commercial Medical Benefit Drug Policies](#) on UHCprovider.com; we will no longer maintain Oxford-specific Medical Benefit Drug Policy versions. The *Oxford Policy Update Bulletin* will continue to announce changes to Medical Benefit Drug Policies (Clinical Policies) through April 2022. After that time, updates to the Medical Benefit Drug Policies will only be announced in the *UnitedHealthcare Commercial Medical Policy Update Bulletin*.

Policy Title	Status	Effective Date
Benlysta® (Belimumab)	Revised	Apr. 1, 2022
Cardiovascular Disease Risk Tests	Updated	Apr. 1, 2022
Deep Brain and Cortical Stimulation	Updated	Mar. 1, 2022
Drug Coverage Criteria: New and Therapeutic Equivalent Medications	Revised	Apr. 1, 2022
Drug Coverage Guidelines <ul style="list-style-type: none"> • Leqvio (Inclisiran) • Tezspire (Tezepelumab-ekko) • Vyvgart (efgartigimod alfa-fcab) 	Revised	Mar. 1, 2022
Drug Coverage Guidelines <ul style="list-style-type: none"> • Anaprox DS (Naproxen) • Besremi (Ropeginterferon-Alfa-2b-Njft) • Bylvay (Odevixibat) • Chenodal (Chenodiol) • Chlorpromazine Concentrate (Generic Thorazine) • Doptelet (Avatrombopag) • Forteo (Teriparatide) • Genotropin (Somatropin) • Genotropin Miniquick (Somatropin) • Humatrope (Somatropin) • Increlex (Mecasermin) • Kineret (Anakinra) • Livmarli (Maralixibat) • Myfembree (Relugolix and Estradiol Hemihydrate/ Norethindrone) • Norditropin (Somatropin) • Norditropin Flexpro (Somatropin) • Norditropin Nordiflex (Somatropin) • Nutropin and Nutropin AQ (Somatropin) • Nutropin AQ Nuspin (Somatropin) • Omnitrope (Somatropin) • OriaHnn (Elagolix/Estradiol/Norethindrone Acetate) • Promacta (Eltrombopag) 	Revised	Apr. 1, 2022

Policy Title	Status	Effective Date
<ul style="list-style-type: none"> ● Rezurock (Belumosudil) ● Saizen (Somatropin) ● Sandostatin (Octreotide Acetate) ● Sandostatin (Brand Only) (Octreotide Acetate) ● Seglentis (Celecoxib/ Tramadol) ● Selzentry (Maraviroc) ● Serostim (Somatropin) ● Skytrofa (Lonapegsomatropin-Tcgd) ● Soaanz (Torsemide) ● Sucraid (Sacrosidase) ● Tavalisse (Fostamatinib Disodium Hexahydrate) ● Tavneos (Avacopan) ● Verzenio (Abemaciclib) ● Vitrakvi® (Larotrectinib) ● Vocabria (Cabotegravir) ● Xpovio (Selinexor) ● Zimhi Prefilled Syringe (Naloxone Hydrochloride) ● Zomacton (Somatropin) ● Zorbtive (Somatropin) 		
Functional Endoscopic Sinus Surgery (FESS)	Revised	Apr. 1, 2022
Intravitreal Corticosteroid Implants	New	May 1, 2022
Ketalar® (Ketamine) and Spravato® (Esketamine)	Revised	May 1, 2022
Leqvio® (Inclisiran)	New	Mar. 1, 2022
Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) Scan – Site of Service	Updated	Apr. 1, 2022
Negative Pressure Wound Therapy	Revised	May 1, 2022
Obstructive and Central Sleep Apnea Treatment	Revised	May 1, 2022
Oncology Medication Clinical Coverage	Updated	Apr. 1, 2022
Ophthalmologic Policy: Vascular Endothelial Growth Factor (VEGF) inhibitors	New	May 1, 2022
Respiratory Interleukins (Cinqair®, Fasenna®, & Nucala®)	Revised	Apr. 1, 2022
Ryplazim® (Plasminogen, Human-Tvmh)	Revised	Apr. 1, 2022
Self-Administered Medications	New	May 1, 2022
Skin and Soft Tissue Substitutes	Revised	Apr. 1, 2022
Somatostatin Analogs	Revised	May 1, 2022
Subcutaneous Implantable Naltrexone Pellets	New	May 1, 2022
Testosterone Replacement or Supplementation Therapy	New	May 1, 2022
Tezspire™ (Tezepelumab)	New	Mar. 1, 2022
Transcatheter Heart Valve Procedures	Updated	Mar. 1, 2022
Vyvgart™ (Efgartigimod Alfa-Fcab)	New	Mar. 1, 2022
Xolair® (Omalizumab)	Revised	Apr. 1, 2022

Administrative Policy Updates

Policy Title	Status	Effective Date
Dialysis Services	Updated	Mar. 1, 2022
Durable Medical Equipment, Orthotics, Medical Supplies and Repairs/Replacements	Updated	Mar. 1, 2022
Specialty Pharmacy Requirements for UnitedHealthcare Commercial Plan Members	Revised	May 1, 2022

General Information

The inclusion of a health service (e.g., test, drug, device or procedure) in this bulletin indicates only that UnitedHealthcare Oxford® is adopting a new policy and/or updated, revised, replaced or retired an existing policy; it does not imply that UnitedHealthcare Oxford® provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

Note: The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare Oxford® reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare Oxford® respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Policy Update Bulletin was developed to share important information regarding UnitedHealthcare Oxford® Clinical, Administrative, and Reimbursement Policy updates. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare Oxford® follows such applicable federal and/or state law.

Policy Update Classifications

New

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device or procedure)

Updated

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

Revised

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

Replaced

An existing policy has been replaced with a new or different policy

Retired

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of UnitedHealthcare Oxford® Medical and Administrative Policies is available at OxfordHealth.com > Providers > Tools & Resources > Medical Information > [Medical and Administrative Policies](#) or at UHCprovider.com > Policies and Protocols > Commercial Policies > [UnitedHealthcare Oxford Clinical, Administrative and Reimbursement Policies](#). Refer to the back of the member's health care ID card for the applicable website.